Amporin Pharmaceuticals Wins New BioTech Development Company of the Year

---

---

Winners in the Corporate LiveWire Global Awards 2024/25

Amporin Pharmaceuticals is a groundbreaking biotech startup poised to transform the treatment of degenerative diseases. Founded in Basel in 2024 by a team of experienced drug development professionals, the company is dedicated to pioneering a new class of small molecule amyloid pore inhibitors. These innovative compounds have the potential to provide the first effective acute oral disease-modifying treatments for a range of deadly conditions associated with protein misfolding and aggregation. Degenerative diseases such as Alzheimer’s, Parkinson’s, ALS and type II diabetes impact over half a billion people worldwide, resulting in an estimated 3.6 million deaths annually. Amporin Pharmaceuticals is addressing this challenge with a novel approach — targeting the root cause of these diseases: the formation of toxic amyloid pores.
 
Recent scientific breakthroughs suggest that many degenerative diseases stem from the accumulation of toxic soluble oligomers and amyloid pores within cell membranes. These structures puncture holes in cells, disrupting their function and ultimately leading to cell death. Unlike traditional treatments that focus on symptom management, Amporin Pharmaceuticals has developed three entirely new classes of small molecule drugs designed to block, dissolve and degrade these toxic amyloid pores. By eliminating the primary drivers of neurodegeneration and cellular dysfunction, these compounds have demonstrated remarkable efficacy in preclinical studies. With a mission to develop a simple pill capable of curing six major degenerative diseases, Amporin Pharmaceuticals is at the forefront of an urgent medical revolution.
 
The judging panel were particularly impressed by the bold innovation which has allowed Amporin Pharmaceuticalsto make great strides in their sector, where progress is often incremental. The biotech specialists’ proprietary technology, combined with a targeted focus on the molecular origins of neurodegeneration, places the company at the cutting edge of medical science. The ability to protect and repair cell membranes at a fundamental level represents a paradigm shift in drug development — one that could redefine the future of medicine. Amporin Pharmaceuticals stands on the cusp of a major breakthrough; one with the potential to save millions of lives and dramatically reduce the economic burden of degenerative diseases.

Website: www.amporin.com